Recombinant programmed cell death protein 1 functions as an immune check point blockade and enhances anti-cancer immunity. 2022

Juyoung Hwang, and Eun-Koung An, and Wei Zhang, and Hae-Bin Park, and So-Jung Kim, and Dhananjay Yadav, and Jihoe Kim, and Inho Choi, and Minseok Kwak, and Peter Cw Lee, and Xiaoyan Zhang, and Jianqing Xu, and Jun-O Jin
Shanghai Public Health Clinical Center & Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, 201508, China; Department of Medical Biotechnology, Yeungnam University, Gyeongsan, 38541, South Korea; Research Institute of Cell Culture, Yeungnam University, Gyeongsan, 38541, South Korea.

Effective cancer therapy aims to treat not only primary tumors but also metastatic and recurrent cancer. Immune check point blockade-mediated immunotherapy showed promising effect against tumors; however, it still has a limited effect in metastatic or recurrent cancer. Here, we extracted recombinant murine programmed death-1 (rmPD-1) proteins. The extracted rmPD-1 effectively bound to CT-26 and 4T1 cells expressing PD-L1 and PD-L2. The rmPD-1 did not alter the activation of dendritic cells (DCs); however, rmPD-1 promoted T cell-mediated anti-cancer immunity against CT-26 tumors in mice. Moreover, rmPD-1 decorated thermal responsive hybrid nanoparticles (piHNPs) promoted apoptotic and necrotic cell death of CT-26 cells in response to laser irradiation at 808 nm consequently, it promoted anti-tumor effects against the 1st challenged CT-26 tumors in mice. In addition, piHNP-mediated cured mice from 1st challenged CT-26 was also prevented the 2nd challenged lung metastatic tumor growth, which was dependent of cancer antigen-specific memory T cell immunity. It was also confirmed that the lung metastatic growth of 2nd challenged 4T1 breast cancer was also prevented in cured mice from 1st challenged 4T1 by piHNP. Thus, these data demonstrate that rmPD-1 functions as an immune checkpoint blockade for the treatment of tumors, and piHNPs could be a novel therapeutic agent for preventing cancer metastasis and recurrence.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D053758 Nanoparticles Nanometer-sized particles that are nanoscale in three dimensions. They include nanocrystaline materials; NANOCAPSULES; METAL NANOPARTICLES; DENDRIMERS, and QUANTUM DOTS. The uses of nanoparticles include DRUG DELIVERY SYSTEMS and cancer targeting and imaging. Nanocrystalline Materials,Nanocrystals,Material, Nanocrystalline,Materials, Nanocrystalline,Nanocrystal,Nanocrystalline Material,Nanoparticle
D061026 Programmed Cell Death 1 Receptor An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE. PD-1 Protein,Programmed Cell Death 1 Protein,Programmed Cell Death Protein 1,Antigens, CD279,CD279 Antigen,PD-1 Receptor,PD1 Receptor,Antigen, CD279,CD279 Antigens,PD 1 Protein,PD 1 Receptor,Receptor, PD-1,Receptor, PD1

Related Publications

Juyoung Hwang, and Eun-Koung An, and Wei Zhang, and Hae-Bin Park, and So-Jung Kim, and Dhananjay Yadav, and Jihoe Kim, and Inho Choi, and Minseok Kwak, and Peter Cw Lee, and Xiaoyan Zhang, and Jianqing Xu, and Jun-O Jin
December 2018, Journal of thoracic disease,
Juyoung Hwang, and Eun-Koung An, and Wei Zhang, and Hae-Bin Park, and So-Jung Kim, and Dhananjay Yadav, and Jihoe Kim, and Inho Choi, and Minseok Kwak, and Peter Cw Lee, and Xiaoyan Zhang, and Jianqing Xu, and Jun-O Jin
March 2024, Cancer,
Juyoung Hwang, and Eun-Koung An, and Wei Zhang, and Hae-Bin Park, and So-Jung Kim, and Dhananjay Yadav, and Jihoe Kim, and Inho Choi, and Minseok Kwak, and Peter Cw Lee, and Xiaoyan Zhang, and Jianqing Xu, and Jun-O Jin
December 2019, Annals of translational medicine,
Juyoung Hwang, and Eun-Koung An, and Wei Zhang, and Hae-Bin Park, and So-Jung Kim, and Dhananjay Yadav, and Jihoe Kim, and Inho Choi, and Minseok Kwak, and Peter Cw Lee, and Xiaoyan Zhang, and Jianqing Xu, and Jun-O Jin
December 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Juyoung Hwang, and Eun-Koung An, and Wei Zhang, and Hae-Bin Park, and So-Jung Kim, and Dhananjay Yadav, and Jihoe Kim, and Inho Choi, and Minseok Kwak, and Peter Cw Lee, and Xiaoyan Zhang, and Jianqing Xu, and Jun-O Jin
November 2020, JTO clinical and research reports,
Juyoung Hwang, and Eun-Koung An, and Wei Zhang, and Hae-Bin Park, and So-Jung Kim, and Dhananjay Yadav, and Jihoe Kim, and Inho Choi, and Minseok Kwak, and Peter Cw Lee, and Xiaoyan Zhang, and Jianqing Xu, and Jun-O Jin
December 2016, Cancer immunology, immunotherapy : CII,
Juyoung Hwang, and Eun-Koung An, and Wei Zhang, and Hae-Bin Park, and So-Jung Kim, and Dhananjay Yadav, and Jihoe Kim, and Inho Choi, and Minseok Kwak, and Peter Cw Lee, and Xiaoyan Zhang, and Jianqing Xu, and Jun-O Jin
January 2022, Frontiers in oncology,
Juyoung Hwang, and Eun-Koung An, and Wei Zhang, and Hae-Bin Park, and So-Jung Kim, and Dhananjay Yadav, and Jihoe Kim, and Inho Choi, and Minseok Kwak, and Peter Cw Lee, and Xiaoyan Zhang, and Jianqing Xu, and Jun-O Jin
September 2023, The British journal of dermatology,
Juyoung Hwang, and Eun-Koung An, and Wei Zhang, and Hae-Bin Park, and So-Jung Kim, and Dhananjay Yadav, and Jihoe Kim, and Inho Choi, and Minseok Kwak, and Peter Cw Lee, and Xiaoyan Zhang, and Jianqing Xu, and Jun-O Jin
November 2017, JAMA dermatology,
Juyoung Hwang, and Eun-Koung An, and Wei Zhang, and Hae-Bin Park, and So-Jung Kim, and Dhananjay Yadav, and Jihoe Kim, and Inho Choi, and Minseok Kwak, and Peter Cw Lee, and Xiaoyan Zhang, and Jianqing Xu, and Jun-O Jin
October 2023, International journal of molecular sciences,
Copied contents to your clipboard!